Open company graph database — free web & API
Login

DAIICHI SANKYO ITALIA S.p.A.

Daiichi Sankyo, Italia S.p.AAlias第一三共イタリア株式会社AliasDaiichi SankyoAliasDaiichi Sankyo Italia S.p.A.Alias
Ticker
—
Listed market
—
Country
Italy
Employees (non-consolidated)
—
Related companies
1
§01

Basic information

BASIC
Head office
Chief executive
Employees (non-consolidated)
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

2
VANFLYTAVanflyta
§04

Related companies

1 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Ranbaxy Laboratories Limited
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

15 EVENTS

The origins of Daiichi Sankyo Europe date back to Luitpold-Werk, a pharmaceutical company founded on January 22, 1910 in Munich, Germany.Sources

Since 1962, the company has strengthened its international presence by opening branches in Brazil, Spain, Switzerland, and Italy, and by building a second manufacturing plant in Altkirch, France.Sources

In Europe, the network of scientific drug informants is strengthened by recruiting human resources from Merck Serono in Ireland and Italy.Sources

After the earthquake that struck Japan, Daiichi Sankyo Europe supported its Japanese colleagues.Sources

The company launched a solidarity initiative called "Daiichi Sankyo Children Aid" to support many children in the areas affected by the earthquake in Japan.Sources

At the European Society of Cardiology (ESC) congress, Daiichi Sankyo presented the phase 3 results of the Hokusai-VTE study with edoxaban, an Xa inhibitor.Sources

A month later the company announced the results of the phase 3 ENGAGE AF-TIMI study conducted in patients with non-valvular atrial fibrillation.Sources

Daiichi Sankyo acquired the biotechnology company Ambit Biosciences.Sources

At our German manufacturing plant in Pfaffenhofen, near Munich, a new facility for Pharmaceutical Development was inaugurated, employing over 100 staff in a 5,000 square meter environment.Sources

European approval of Edoxaban, an Xa inhibitor, and launch in respective markets.Sources

Closing of an exclusive licensing agreement with Esperion Therapeutics for the commercialization of bempedoic acid and the fixed-dose combination of bempedoic acid/ezetimibe.Sources

In response to the Covid-19 pandemic, the company undertook various initiatives across Europe.Sources

In April 2020, the European Commission approved the use in Europe of bempedoic acid and its fixed-dose combination with ezetimibe.Sources

In January 2021, the European Commission approved Daiichi Sankyo's first oncology product.Sources

In April 2023 we opened our new Canadian branch, part of the Daiichi Sankyo European network.Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑